Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Non-coding RNAs in disease: from mechanisms to therapeutics
Non-coding RNAs (ncRNAs) are a heterogeneous group of transcripts that, by definition, are
not translated into proteins. Since their discovery, ncRNAs have emerged as important …
not translated into proteins. Since their discovery, ncRNAs have emerged as important …
MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside
Non-coding RNAs represent a significant proportion of the human genome. After having
been considered as 'junk'for a long time, non-coding RNAs are now well established as …
been considered as 'junk'for a long time, non-coding RNAs are now well established as …
An overview of microRNAs
SM Hammond - Advanced drug delivery reviews, 2015 - Elsevier
The discovery of the first microRNA (miRNA) over 20 years ago has ushered in a new era in
molecular biology. There are now over 2000 miRNAs that have been discovered in humans …
molecular biology. There are now over 2000 miRNAs that have been discovered in humans …
[HTML][HTML] A comprehensive review of cancer MicroRNA therapeutic delivery strategies
A Forterre, H Komuro, S Aminova, M Harada - Cancers, 2020 - mdpi.com
In the field of molecular oncology, microRNAs (miRNAs) and their role in regulating
physiological processes and cancer pathogenesis have been a revolutionary discovery over …
physiological processes and cancer pathogenesis have been a revolutionary discovery over …
New insights into long noncoding RNAs and their roles in glioma
Z Peng, C Liu, M Wu - Molecular cancer, 2018 - Springer
Glioma is one of the most prevalent types of primary intracranial carcinoma with varying
malignancy grades I–IV and histological subtypes, including astrocytomas, glioblastoma …
malignancy grades I–IV and histological subtypes, including astrocytomas, glioblastoma …
microRNA therapeutics in cancer—an emerging concept
MicroRNAs (miRNAs) are an evolutionarily conserved class of small, regulatory non-coding
RNAs that negatively regulate protein coding gene and other non-coding transcripts …
RNAs that negatively regulate protein coding gene and other non-coding transcripts …
LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer
A Bhan, SS Mandal - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2015 - Elsevier
Non-coding RNAs (ncRNAs) are emerging classes of regulatory RNA that play key roles in
various cellular and physiological processes such as in gene regulation, chromatin …
various cellular and physiological processes such as in gene regulation, chromatin …
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
C Marchetti, F De Felice, A Romito, V Iacobelli… - Seminars in Cancer …, 2021 - Elsevier
Ovarian cancer (OC) remains a fatal malignancy because most patients experience
recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …
recurrent disease, which is resistant to chemotherapy. The outcomes for patients with …
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
B van Zyl, D Tang, NA Bowden - Endocrine-related cancer, 2018 - erc.bioscientifica.com
Ovarian cancer has poor survival rates due to a combination of diagnosis at advanced
disease stages and disease recurrence as a result of platinum chemotherapy resistance …
disease stages and disease recurrence as a result of platinum chemotherapy resistance …
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy
KKW To, Z Huang, H Zhang, CR Ashby Jr, L Fu - Drug Resistance Updates, 2024 - Elsevier
Multidrug resistance (MDR) is one of the primary factors that produces treatment failure in
patients receiving cancer chemotherapy. MDR is a complex multifactorial phenomenon …
patients receiving cancer chemotherapy. MDR is a complex multifactorial phenomenon …